The earnings call presented a generally positive outlook for Belite Bio, with significant progress in clinical trials for Tinlarebant and a robust financial position. However, increased operating expenses and pending regulatory details introduce some uncertainty.

Company Guidance -

Q2 2025

During the Belite Bio First Quarter 2025 Earnings Call, the company provided several key metrics and updates regarding their clinical trials and financial standing. In the Stargardt disease program, the Phase 3 DRAGON trial, involving 104 subjects, has moved forward successfully with the Data Safety Monitoring Board (DSMB) recommending no changes to the trial size and suggesting data submission for regulatory review. The DRAGON 2 trial has enrolled 16 out of a targeted 60 subjects. For geographic atrophy, the Phase 3 PHOENIX trial has enrolled 464 subjects out of a planned 500, with full enrollment expected by Q3 2025. Financially, the company reported R&D expenses of $9.4 million and G&A expenses of $6.1 million for Q1 2025, resulting in a net loss of $14.3 million. Despite the increased expenses, primarily due to share-based compensation, Belite Bio maintains a strong financial position with $157.4 million in cash and equivalents, ensuring a cash runway to complete current clinical trials.

Promising Clinical Progress for Tinlarebant

The Phase 3 DRAGON trial for Tinlarebant showed promising interim results with the DSMB recommending submission for further regulatory review. The trial is on track for completion by the end of the year.

Strong Financial Position

Belite Bio reported a cash increase of $12.3 million for the quarter, leaving the company with $157.4 million in cash and equivalents. The company expects a full year cash runway to complete all current clinical trials.

Phase 3 PHOENIX Trial Advancements

The PHOENIX trial for geographic atrophy has enrolled 464 subjects with a total target of 500. Enrollment is expected to be completed in Q3 2025.

Low Withdrawal Rates in Clinical Trials

DRAGON trial showed less than a 10% overall withdrawal rate, and the PHOENIX trial's dropout rate is approximately 20%, which is lower than comparables.

Belite Bio, Inc. ADR (BLTE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BLTE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 11, 2025	2025 (Q2)	-0.41 / -	-0.31	―	―	―
May 14, 2025	2025 (Q1)	-0.35 / -0.45	-0.27	-66.67% (-0.18)	―
Mar 17, 2025	2024 (Q4)	-0.31 / -0.32	-0.25	-28.00% (-0.07)
Nov 12, 2024	2024 (Q3)	-0.29 / -0.28	-0.4	30.00% (+0.12)
Aug 09, 2024	2024 (Q2)	-0.26 / -0.31	-0.26	-19.23% (-0.05)
May 14, 2024	2024 (Q1)	-0.28 / -0.27	-0.33	18.18% (+0.06)
Mar 12, 2024	2023 (Q4)	-0.30 / -0.25	-0.37	32.43% (+0.12)
Nov 14, 2023	2023 (Q3)	-0.32 / -0.40	-0.11	-263.64% (-0.29)
Aug 09, 2023	2023 (Q2)	-0.30 / -0.26	-0.08	-225.00% (-0.18)
May 10, 2023	2023 (Q1)	- / -	-0.235	―		―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BLTE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$60.89	$61.60	+1.17%
Mar 17, 2025	$67.44	$67.81	+0.55%
Nov 12, 2024	$78.64	$81.15	+3.19%
Aug 09, 2024	$49.48	$48.55	-1.88%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Belite Bio, Inc. ADR (BLTE) report earnings?

Belite Bio, Inc. ADR (BLTE) is schdueled to report earning on Aug 11, 2025, Before Open (Confirmed).

What is Belite Bio, Inc. ADR (BLTE) earnings time?

Belite Bio, Inc. ADR (BLTE) earnings time is at Aug 11, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BLTE EPS forecast?

BLTE EPS forecast for the fiscal quarter 2025 (Q2) is -0.41.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing